Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that nearly 40% of patients with severe alopecia areata who showed eyebrow or eyelash regrowth on baricitinib 4 mg achieved significant scalp hair regrowth by the second year of treatment.

In two phase 3 clinical trials, this study found that adults with severe alopecia areata receiving baricitinib experienced significant hair regrowth on the scalp, eyebrows, and eyelashes over 36 weeks compared to placebo, although longer-term data are needed to fully assess benefits and risks.

This review provides insights and guidelines for clinicians and patients on assessing the risks and benefits of ritlecitinib for adolescents with alopecia areata, emphasizing shared decision-making and management strategies.

5-ARI therapy may help prevent prostate cancer progression.

This study found that baricitinib can counteract the cytokine-driven reduction of the enzyme PADI1 in human keratinocytes, which may help improve skin barrier function in atopic dermatitis by enabling epidermal differentiation.

This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.

This study found that patients receiving active ritlecitinib doses reported greater satisfaction with hair growth compared to placebo, with high agreement observed between clinician evaluations of scalp hair improvement and patient satisfaction through week 48.

This review identified two promising therapeutic targets for drug repurposing to treat refractory angina in patients with angina pectoris without obstructive coronary artery disease: endothelin-1 receptor blockers and soluble guanylate cyclase stimulators.

This case report observed alopecia universalis, a complete hair loss condition, in a patient during a clinical trial with the angiotensin receptor-neprilysin inhibitor sacubitril/alisartan, indicating that ARNI therapy might be associated with such cutaneous reactions.

This research explores innovative methods to enhance drug delivery to the brain, including techniques like focal intra-arterial administration and temporary blood-brain barrier opening, aimed at improving treatment for brain disorders, the authors report.

In this report, NICE has approved ritlecitinib, an oral kinase inhibitor, as the first recommended treatment for severe alopecia areata in individuals aged 12 and older.

This study documented successful use of Brevilin-A, a topical treatment, in pediatric patients with alopecia areata, indicating it as a potentially safe and effective option for managing mild-moderate cases and resistant forms of the disease.

This industry update reports on various advancements in therapeutic delivery during July 2018, highlighting active mergers, collaborations, and potential developments across fields like gene therapy, immuno-oncology, and rare diseases treatment; however, no new clinical results are presented.

This study observed that applying a GMP-grade botanical extract to the scalp increased Bcl-2 levels, potentially preventing premature hair follicle apoptosis in chemotherapy and radiotherapy-induced alopecia.

This case study reports the successful use of abrocitinib for treating severe alopecia areata in a 14-year-old patient, demonstrating significant hair regrowth and suggesting the need for sustained JAK1 inhibition to prevent relapse.

This study is collecting real-world data to evaluate abrocitinib and conventional systemic treatments in moderate-to-severe atopic dermatitis across five European registers over a three-year period.

In this study, data from multiple sources found that Baricitinib significantly promoted hair regrowth and improved patient-reported outcomes in those with severe alopecia, with minimal side effects, over a 36-week period.

In this study, the researchers developed a deep learning framework to pre-emptively screen for adverse drug effects, showing strong predictive performance, including for increased bleeding risks with edoxaban compared to other anticoagulants.

In this retrospective study, researchers found that baricitinib was effective for treating moderate to severe alopecia areata, with response rates in 24 patients comparable to existing real-world data, and no new safety concerns were identified.

In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.

A man developed an allergic skin reaction after using brimonidine for rosacea.

Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.

This study found that 10,11-dibrominecrebanine (2Br-Cre) and Stephanine demonstrate significant anti-inflammatory and analgesic properties in various experimental models, with 2Br-Cre showing enhanced efficacy over Cre and both compounds potentially mediating their analgesic effects through opioid receptors.

This study found that 95% of untreated advanced-stage follicular lymphoma patients responded to a single course of the Bexxar regimen, with 75% achieving complete remission and remaining disease-free for years.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

This study found that 45.5% of alopecia areata patients treated with ritlecitinib 50 mg daily achieved significant hair regrowth, with most maintaining their response over 24 months.

This article describes the development milestones and recent approvals of ritlecitinib for treating severe alopecia areata, with approvals in the USA and Japan and ongoing regulatory reviews in other regions.

In this study, researchers report that CDK inhibitors like palbociclib and ribociclib, initially developed for cancer therapy, show potential in treating neutrophilic inflammation-related conditions such as ARDS and psoriasis, although their clinical repurposing requires further research on safety and dose adjustments.

This report describes a case in which poststreptococcal reactive arthritis in a girl was effectively treated with naproxen, and highlights the importance of considering nongroup A Streptococcus in similar presentations.